By Bernadette Toner

Qiagen is betting that its $90 million all-cash acquisition of PCR assay developer SABiosciences, announced last week and expected to close before the end of the year, will be of particular interest for its pharma and biotech customers developing companion diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.